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Malignant ﬁbrous histiocytoma (MFH) usually presents in the extremities or retroperitoneum. Cases involving the kidney are rare
and portend a poor prognosis. Although radical nephrectomy is the most beneﬁcial curative choice for this neoplasm, patients
are often treated with adjuvant chemotherapy due to high risk of local recurrence and distant metastases. We describe a case of
a 68-year-old woman aﬀected by MFH, treated with both nephrectomy and radiotherapy without systemic therapy showing an
unexpected twenty-four-month postsurgery survival outcome.
1.Introduction
Malignant ﬁbrous histiocytoma (MFH) is the most common
subtype of soft-tissue sarcoma in adults, and its charac-
teristics were ﬁrstly described in 1964 by O’Brien and
Stout [1]. MFH frequently localizes to the extremities and
retroperitoneum, and rarely to the kidney [2–5]. Renal
localization is characterized by high risk of local and
distant recurrence, unfavorable prognosis, and complicated
clinical and histopathological diagnosis, which is very often a
diagnosis of exclusion. The role of adjuvant therapy for renal
MFH is unclear, because of the insuﬃcient number of cases
oﬀered. We describe here a case of primary renal MFH and
the beneﬁcial role of adjuvant radiotherapy treatment.
2.CaseReport
A 68-year-old woman with abdominal pain and low-grade
fever of two-month duration was admitted to the hospital.
Clinical examination was unremarkable and no palpable
mass was found by physical inspection. Laboratory analysis
revealed anemia (Hb 9.9gm/dL) and leukocytosis (23000/μL
with normal range: 4000−11000/μL). All the other bio-
chemical data, including renal function and urine analysis,
were normal. Chest X ray was unremarkable. Contrast-
enhanced computed tomography (CT) showed a large mass
of approximately 8cm in diameter adjacent to the lower
pole of the right kidney, which exhibited enhancement with
contrast medium. The contralateral kidney and adjacent
organs appeared normal and no enlarged lymph nodes
were observed in the abdomen. A magnetic resonance
imaging (MRI) was recommended but the patient refused
the procedure because of severe claustrophobia. Based on
the data collected, the preoperative diagnosis was of right
renal cell carcinoma. Radical right nephrectomy was then
performed by thoracoabdominal approach. Postoperative
course was uneventful. The gross specimen included tissue
from right kidney, ureter, right renal hilum and paracaval
nodes. Nephrectomy specimen showed a pale yellow color,
an uncircumcised solid lesion (maximum diameter 11cm)
conﬁned to the lower pole of the right kidney, inﬁltrating the
renalcapsuleandtheperirenaladiposetissue.Multiplesurgi-
cal margins were not involved. The tumor was histologically
diagnosed as ﬁbroblastic-pleomorphic type of malignant
ﬁbrous histiocytoma. After surgery, the patient was treated
with adjuvant radiotherapy without systemic therapy. The
tumor bed was treated with a computer tomography-based
approach with a combination of three ﬁelds (left anterior
oblique, right posterior oblique, and right lateral oblique)
using an 18 MV linear accelerator (Figure 1).2 Case Reports in Medicine
Body
Ref Left kidney
0.00cm (# 30/60)
+Z
P
R+ X
(%)
107.00
100.00
95.00
90.00
Figure 1: Computer tomography-based treatment plan with a combination of three ﬁelds (left anterior oblique, right posterior oblique, and
right lateral oblique).
Treatment was given daily with a total dose of 50Gy at
2.0Gy per fraction, ﬁve days per week. Dose variation in the
planning target volume (PTV) was kept within +7 and −5%
of the prescribed dose according to ICRU recommendations
[6, 7]. Radiation dose distribution was optimized to maxi-
mize target volume coverage while minimizing the dose to
the organs at risk. Dose-volume histograms (DVHs) were
recorded for the left kidney, liver, spinal cord, CTV, and PTV
(Figure 2).
We adopted the Emami tolerance doses for the left
kidney, which recommend TD5/5 of 50, 30, and 23Gy for
irradiation of one third of, two thirds of, or the entire kidney
[8].
No acute or late toxicity and no postirradiation compli-
cations occurred, except for a G1 (RTOG toxicity criteria)
acutecutaneous toxicity. The outcome shows that the patient
remains alive twenty-four months after the surgery, without
local recurrence or metastases.
3. Discussion
Malignant ﬁbrous histiocytoma is a common soft-tissue
sarcoma, usually occurring during the seventh decade of
life. Fifty percent of cases originate in the lower limbs,
24% in the upper limbs, 16% in the trunk, and 9%
in the retroperitoneum [2–5]. Primary renal MFH is a
rare lesion characterized by symptoms common to other
renal mass lesions. In the case reported here, preoperative
diﬀerentiation from renal cell carcinoma was not feasible
due to the atypical symptoms presented by the patient,
such as abdominal pain and low-grade fever. The diagnostic
imaging frequently includes CT and MRI but the deﬁnitive
diagnosis is often a diagnosis of exclusion conﬁrmed by
histological analysis [9, 10], since immunohistochemistry
allows a better deﬁnition of the histological characteris-
t i c so fM F H .T h ec a s er e p o r t e dh e r ew a sh i s t o l o g i c a l l y
identiﬁed as a ﬁbroblastic-pleomorphic type of MFH. A
renal biopsy was considered to identify the neoplasm as
primary RCC. However, the clinical data indicated that a
neoplasm and a nephrectomy would have been the curative
choice in any case. Therefore, the renal biopsy was believed
unnecessary. An inﬂammatory variety of MFH characterized
by intense inﬂammatory inﬁltrate rich in neutrophils are
also known, and although only a few cases of this type of
MFH have been reported, it seems to be associated with
a worse prognosis compared to ﬁbroblastic-pleomorphic
MFH [11, 12]. Although radical nephrectomy is currently
the most beneﬁcial treatment of MFH, adjuvant treatment is
required to minimize the risk of local recurrence and distant
metastases [9, 10, 13, 14]. A review of the literature suggests
that cases of renal MFH have been reported describing
clinicopathological [15–20] or imaging features [17–19]a n d
surgery or chemotherapeutic treatment [9, 21, 22], but only
minordatahavebeenreportedaboutradiotherapy[4,10,23,
24].
Diﬀerent schedules of chemotherapy have been used for
MFH, but due to the small number of cases, the conclusion
regarding adjuvant chemotherapy is unclear [4, 9, 13, 18, 21,
22]. A similar scenario exists for the eﬃcacy of the adjuvantCase Reports in Medicine 3
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Figure 2: Dose-volume histogram: liver (green), left kidney (purple), body (pink), spinal cord (blue), CTV (red), and PTV (orange).
radiotherapy on renal MFH. For the case presented in this
study, no systemic therapy was administered and the patient
was treated with radiotherapy alone. The maximum dose
used for the left kidney was 14Gy and the median dose was
11Gy. Although the mean dose did not exceed tolerance,
a total dose of 50Gy was administered in order not to
exceed the dose constraints. As previously reported, local
recurrence and distant metastases are frequent in patients
aﬀected by renal MFH, leading to a poor prognosis for this
type of tumor [11, 14, 15]. The case described by Singh
and coworkers [11] was treated only with surgery and died
within one month of diagnosis. Ishibiki and coworkers [14]
describedacaseofstoriform-pleomorphicmalignantﬁbrous
histiocytoma arising from perirenal tissue not treated with
adjuvant therapy that developed local recurrence in the left
retroperitoneal space after a followup period of 11 months.
The unexpected outcome of the patient presented in this
study seems to favor the use of adjuvant radiotherapy in the
treatment of renal MFH. Although with a shorter followup
time, a similar result has been showed by Eroylu and
coworkers [23],whichdescribedarecurrence-freesurvivalof
ﬁfteen months after surgery followed by radiotherapy with
6,600rad. The eﬃcacy of radiotherapy and its impact on
this rare disease remains, however, unclear. It also has to be
considered that signiﬁcant technological improvements in
radiotherapy have been achieved during the last years (e.g.,
multileaf collimators, electronic portal imaging, electronic
administrative and image-data management systems, and
computed tomography scanners) and that they might have
improved also treatment results. The treatment of MFH
has not been standardized yet and further studies would be
necessary to improve the survival of patients and to better
evaluate the most appropriate adjuvant treatment for this
rare neoplasm.
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